Peter Graham Rose, MD
Professor and Section Head
Cleveland Clinic
Dept. of OB/GYN
9500 Euclid Ave
A-81
Cleveland,
OH
USA
44195
Papers:
51
A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study
59
Does adjuvant pelvic radiation therapy improve survival in patients with uterine serous carcinoma who received adjuvant chemotherapy?
102
The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced stage cancer of müllerian origin treated with neoadjuvant chemotherapy
118
Referral of obese endometrial cancer survivors to a bariatric specialist: weight loss attempts initiated and barriers to change
253
The impact of age on the risk of 30-day postoperative morbidity and mortality in patients undergoing surgery for ovarian cancer
363
Investigation of the timing of neoadjuvant chemotherapy on survival in advanced stage ovarian cancer
404
Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma
A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology / gynecologic oncology group study